contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nexstim-receives-system-order-from-us-clinic

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

It looks like it’s going down to the wire again, but that’s how it went last year too:

canhealth.com              CABHI awards $2.8M to advance the brain economy | Canadian Healthcare Technology    TORONTO - The Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest, has allocated $2.8 million CAD in funding to eight early- to mid-stage researchers and companies through its Fuel program to accelerate cutting-edge aging and...                             Money for Synaptica.

Biostock – 3 Dec 25              Nexstim: from Helsinki to a global brain revolution    Finnish Nexstim's vision is to offer personalized diagnostics and therapy for serious brain diseases and disorders. To achieve this, it has developed a non-invasive technology for brain stimulation. The treatment works by inducing a weak electrical...         Estimated reading time: 8 minutes

linkedin.com              #neuromodulation #alzheimers #defaultmodenetwork #medtech #ctad25 | Sinaptica...    Today at the 18th Clinical Trials on Alzheimer's Disease (CTAD) in San Diego, Giacomo Koch, MD, PhD, Sinaptica scientific co-founder, and Lisa Fosdick, MS, Chief Clinical & Strategy Officer, will present a poster on our upcoming Phase 3 RETAIN...                             Sinaptica on LinkedIn. Hopefully, this presentation will be published somewhere.

It seems there has been an update to that shareholder register, and that’s why it looks wrong. Leena still has the same number of shares as before, but her first name and last name have just swapped places.

Leena Niemistö also bought personal shares, but apparently didn’t need to issue any announcement?

Skandinaviska Enskilda Banken Ab (publ) Helsinki Branch added 25,922 shares last month. That information does not reach the ultimate owner, but one nuance is that Brainlab’s holdings are also in that same nominee register. At an average price of €14.50, the acquisition of those shares would have totaled €375,869, meaning the big boys (or girls) are accumulating shares there anyway.                   nexstim.com              Nexstim - Nexstimin suurimmat osakkeenomistajat

Nexstim

Press release, Helsinki, 7 October 2025 at 9 AM (EEST) Nexstim Receives System Order from US ClinicNexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system ...

Press release, Helsinki, 7 October 2025 at 9 AM (EEST)&nbsp;Nexstim Receives System Order from US ClinicNexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from a new clinic customer based in western Unites States.The NBS 6 is a new Nexstim product generation that brings the usability of the Nexstim system to a new level. The NBS 6 is currently FDA-cleared for the treatment of major depressive disorder (MDD). Nexstim’s systems are based on the company’s unique navigated transcranial magnetic stimulation (nTMS) technology.Mikko Karvinen, CEO of Nexstim, comments: “The users of our system vary from small clinics to large institutions, and we appreciate the uniqueness of each customer. We warmly welcome this clinic to our user community and wish them the best with adding nTMS treatments to their catalogue of services.”Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO+358 50 326 4101mikko.karvinen@nexstim.com&nbsp;About Nexstim Plc Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.Nexstim shares are listed on Nasdaq First North Growth Market Finland.For more information, please visit <a href="http://www.nexstim.com/">www.nexstim.com </a> <div> <hr> <div>Attachments</div> <div><a href="https://storage.googleapis.com/inderes-widgets-prod-assets/nexstim/attachments/de18c575-7068-4912-a64e-7c7bcdfbbef7/nexstim-plc-press-release-us-order-07102025-final.pdf">Nexstim Plc_Press release_US order_07102025_FINAL.pdf</a></div> </div>